|
[1]
|
Lv, J.C. and Zhang, L.X. (2019) Prevalence and Disease Burden of Chronic Kidney Disease. Advances in Experimental Medicine and Biology, 1165, 3-15. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Ishida, H., Komaba, H., Hamano, N., et al. (2020) Skeletal and Mineral Metabolic Effects of Risedronate in a Rat Model of High-Turnover Renal Osteodystrophy. Journal of Bone and Mineral Metabolism, 38, 501-510. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Tanaka, M., Komaba, H. and Fukagawa, M. (2018) Emerging Association between Parathyroid Hormone and Anemia in Hemodialysis Patients. Therapeutic Apheresis and Dialysis, 22, 242-245. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Kono, K., Fujii, H., Watanabe, K., Goto, S. and Nishi, S. (2021) Relationship between Parathyroid Hormone and Renin-Angiotensin-Aldosterone System in Hemodialysis Pa-tients with Secondary Hyperparathyroidism. Journal of Bone and Mineral Metabolism, 39, 230-236. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Yang, B., Lu, C., Wu, Q., et al. (2016) Parathyroid Hormone, Cardiovascular and All-Cause Mortality: A Meta-Analysis. Clinica Chimica Acta, 455, 154-160. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Quarles, L.D. (2012) Role of FGF23 in Vitamin D and Phosphate Metabolism: Implications in Chronic Kidney Disease. Experimental Cell Research, 318, 1040-1048. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Kawakami, K., Takeshita, A., Furushima, K., et al. (2017) Persis-tent Fibroblast Growth Factor 23 Signalling in the Parathyroid Glands for Secondary Hyperparathyroidism in Mice with Chronic Kidney Disease. Scientific Reports, 7, Article No. 40534. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Brown, E.M. (1983) Four-Parameter Model of the Sigmoidal Relationship between Parathyroid Hormone Release and Extracel-lular Calcium Concentration in Normal and Abnormal Parathyroid Tissue. The Journal of Clinical Endocrinology & Me-tabolism, 56, 572-581. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Demay, M.B., Kiernan, M.S., DeLuca, H.F. and Kronenberg, H.M. (1992) Sequences in the Human Parathyroid Hormone Gene That Bind the 1,25-Dihydroxyvitamin D3 Receptor and Mediate Transcriptional Repression in Response to 1,25-Dihydroxyvitamin D3. Proceedings of the Na-tional Academy of Sciences of the United States of America, 89, 8097-8101. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Brown. A.J., Ritter, C.S., Finch, J.L. and Slatopolsky, E.A. (1999) Decreased Calcium-Sensing Receptor Expression in Hyperplastic Parathyroid Glands of Uremic Rats: Role of Dietary Phosphate. Kidney International, 55, 1284-1292. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Yano, S., Sugimoto, T., Tsukamoto, T., et al. (2000) Asso-ciation of Decreased Calcium-Sensing Receptor Expression with Proliferation of Parathyroid Cells in Secondary Hy-perparathyroidism. Kidney International, 58, 1980-1986. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Fukuda, N., Tanaka, H., Tominaga, Y., et al. (1993) De-creased 1,25-Dihydroxyvitamin D3 Receptor Density Is Associated with a More Severe Form of Parathyroid Hyperplas-ia in Chronic Uremic Patients. Journal of Clinical Investigation, 92, 1436-1443. [Google Scholar] [CrossRef]
|
|
[13]
|
Patel, S.R., Ke, H.Q., Vanholder, R., Koenig, R.J. and Hsu, C.H. (1995) Inhibition of Calcitriol Receptor Binding to Vitamin D Response Elements by Uremic Toxins. Journal of Clinical Inves-tigation, 96, 50-59. [Google Scholar] [CrossRef]
|
|
[14]
|
Lai, T., Frugoli, A., Barrows, B. and Salehpour, M. (2020) Sevelamer Carbonate Crystal-Induced Colitis. Case Reports in Gastrointestinal Medicine, 2020, Article ID: 4646732. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Xiao, X., Liu, Y., Zhong, X., et al. (2019) Sevelamer Hydrochloride Suppresses Proliferation of Parathyroid Cells during the Early Phase of Chronic Renal Failure in Rats. Nephrology (Carlton, Vic.), 24, 127-133. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Thadhani, R.I., Rosen, S., Ofsthun, N.J., et al. (2020) Conversion from In-travenous Vitamin D Analogs to Oral Calcitriol in Patients Receiving Maintenance Hemodialysis. Clinical Journal of the American Society of Nephrology, 15, 384-391. [Google Scholar] [CrossRef]
|
|
[17]
|
Danese, M.D., Lubeck, D., Belozeroff, V., et al. (2020) Real World Use and Effects of Calcimimetics in Treating Mineral and Bone Disorder in Hemodialysis Patients. American Journal of Nephrology, 51, 815-822. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Bucharles, S.G.E., Barreto, F.C. and Riella, M.C. (2019) The Impact of Cinacalcet in the Mineral Metabolism Markers of Patients on Dialysis with Severe Secondary Hyperparathyroidism. Journal Brasileiro de Nefrologia, 41, 336-344. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Tsukamoto, Y., Moriya, R., Nagaba, Y., et al. (1995) Ef-fect of Administering Calcium Carbonate to Treat Secondary Hyperparathyroidism in Nondialyzed Patients with Chronic Renal Failure. American Journal of Kidney Diseases, 25, 879-886. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Pandey, R., Zella, J.B., Zhu, J.G., et al. (2017) Pharmacoki-netics of a New Oral Vitamin D Receptor Activator (2-Methylene-19-Nor-(20S)-1α,25-Dihydroxyvitamin D3) in Pa-tients with Chronic Kidney Disease and Secondary Hyperparathyroidism on Hemodialysis. Drugs in R & D, 17, 597-605. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Fukagawa, M., Shimazaki, R. and Akizawa, T. (2018) Head-to-Head Comparison of the New Calcimimetic Agent Evocalcet with Cinacalcet in Japanese Hemodialysis Patients with Secondary Hyperparathyroidism. Kidney International, 94, 818-825. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Harada, K., Fujioka, A., Konno, M., et al. (2019) Pharmacology of Parsabiv® (Etelcalcetide, ONO-5163/AMG 416), a Novel Allosteric Modulator of the Calcium-Sensing Receptor, for Secondary Hyperparathyroidism in Hemodialysis Patients. European Journal of Pharmacology, 842, 139-145. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
田文, 贺青卿, 姜可伟, 庄大勇, 周鹏. 慢性肾功能衰竭继发甲状旁腺功能亢进外科临床实践专家共识[J]. 中国实用外科杂志, 2016, 36(5): 481-486.
|
|
[24]
|
Neagoe, R.M., Sala, D.T., Voidazan, S., et al. (2021) A Comparative Analysis of Three Types of Parathyroidectomies in Renal Hyperpara-thyroidism Single Centre Prospective Cohort of 77 Patients. Annali Italiani di Chirurgia, 92, 6-12.
|
|
[25]
|
田武国, 汪玲俐, 赵健洁. 继发性甲状旁腺功能亢进手术治疗的现状及进展[J]. 重庆医科大学学报, 2022, 47(11): 1373-1375.
|
|
[26]
|
Stratigis, S., Stylianou, K., Mamalaki, E., et al. (2008) Percutaneous Ethanol Injection Therapy: A Sur-gery-Sparing Treatment for Primary Hyperparathyroidism. Clinical Endocrinology (Oxford), 69, 542-548. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
魏莹, 卓莉, 于明安, 王淑荣, 车颖, 钱林学, 余建军, 郭建琴. 继发性甲状旁腺功能亢进热消融治疗专家共识(2021版) [J]. 中日友好医院学报, 2021, 35(4): 195-202.
|
|
[28]
|
Hu, Z., Han, E., Chen, W., et al. (2019) Feasibility and Safety of Ultrasound-Guided Percutaneous Mi-crowave Ablation for Tertiary Hyperparathyroidism. International Journal of Hyperthermia, 36, 1129-1136. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Ren, M., Zheng, D., Wu, J., et al. (2022) Efficacy and Safety of Radiofrequency Ablation versus Parathyroidectomy for Secondary Hyperparathyroidism in Dialysis Patients: A Sin-gle-Center Retrospective Study. Scientific Reports, 12, Article No. 10289. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
张凌, 刘亚绵. 超声引导下甲状旁腺无水酒精注射治疗继发性甲状旁腺功能亢进症[J]. 中华内科杂志, 2001(11): 58-60+77.
|
|
[31]
|
杜文泽, 陈乐, 吴晓云, 贾军利, 张卫东, 翟江. 超声引导下无水乙醇注射治疗继发性甲状旁腺功能亢进症的临床观察及安全性分析[J]. 中国临床医生杂志, 2017, 45(7): 73-76.
|
|
[32]
|
黄庆龙, 周健美. 继发性甲状旁腺功能亢进症的治疗现状[J]. 安徽医学, 2016, 37(5): 636-638.
|
|
[33]
|
Gong, L., Tang, W., Lu, J. and Xu, W. (2019) Thermal Ablation versus Parathyroidectomy for Secondary Hyperparathyroidism: A Meta-Analysis. International Journal of Surgery, 70, 13-18. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
Chen, Z., Cheng, L., Zhang, W. and He, W. (2022) Ultra-sound-Guided Thermal Ablation for Hyperparathyroidism: Current Status and Prospects. International Journal of Hy-perthermiaermia, 39, 466-474. [Google Scholar] [CrossRef] [PubMed]
|
|
[35]
|
Diao, Z., Wang, L., Li, D. and Liu, W. (2017) Efficacy of Microwave Ablation for Severe Secondary Hyperparathyroidism in Subjects Undergoing Hemodialysis. Renal Failure, 39, 140-145. [Google Scholar] [CrossRef]
|
|
[36]
|
Peng, C., Zhang, Z., Liu, J., et al. (2017) Efficacy and Safe-ty of Ultrasound-Guided Radiofrequency Ablation of Hyperplastic Parathyroid Gland for Secondary Hyperparathyroid-ism Associated with Chronic Kidney Disease. Head & Neck, 39, 564-571. [Google Scholar] [CrossRef] [PubMed]
|
|
[37]
|
Zeng, Z., Peng, C.Z., Liu, J.B., et al. (2020) Efficacy of Ultrasound-Guided Radiofrequency Ablation of Parathyroid Hyperplasia: Single Session vs. Two-Session for Effect on Hypocalcemia. Sci-entific Reports, 10, Article No. 6206. [Google Scholar] [CrossRef] [PubMed]
|
|
[38]
|
Jahangeer, S., Forde, P., Soden, D. and Hinchion, J. (2013) Re-view of Current Thermal Ablation Treatment for Lung Cancer and the Potential of Electrochemotherapy as a Means for Treatment of Lung Tumours. Cancer Treatment Reviews, 39, 862-871. [Google Scholar] [CrossRef] [PubMed]
|
|
[39]
|
Zhuo, L., Peng, L., Zhang, Y.M., et al. (2017) US-Guided Micro-wave Ablation of Hyperplastic Parathyroid Glands: Safety and Efficacy in Patients with End-Stage Renal Disease—A Pilot Study. Radiology, 282, 576-584. [Google Scholar] [CrossRef] [PubMed]
|
|
[40]
|
Li, X., Wei, Y., Shao, H., et al. (2019) Efficacy and Safety of Mi-crowave Ablation for Ectopic Secondary Hyperparathyroidism: A Feasibility Study. International Journal of Hyperther-miaermia, 36, 646-652. [Google Scholar] [CrossRef] [PubMed]
|
|
[41]
|
Li, X., An, C., Yu, M. and Peng, L. (2019) US-Guided Mi-crowave Ablation for Secondary Hyperparathyroidism in Patients after Renal Transplantation: A Pilot Study. Interna-tional Journal of Hyperthermia, 36, 322-327. [Google Scholar] [CrossRef] [PubMed]
|
|
[42]
|
Ma, H., Ouyang, C., Huang, Y., et al. (2020) Comparison of Microwave Ablation Treatments in Patients with Renal Secondary and Primary Hyperparathyroidism. Renal Failure, 42, 66-76. [Google Scholar] [CrossRef]
|
|
[43]
|
Kovatcheva, R.D., Vlahov, J.D., Shinkov, A.D., et al. (2010) High-Intensity Focused Ultrasound to Treat Primary Hyperparathyroidism: A Feasibility Study in Four Patients. Ameri-can Journal of Roentgenology, 195, 830-835. [Google Scholar] [CrossRef]
|
|
[44]
|
Kovatcheva, R.D., Vlahov, J.D., Stoinov, J.I., et al. (2012) High-Intensity Focussed Ultrasound (HIFU) Treatment in Uraemic Secondary Hyperparathyroidism. Nephrology Dialy-sis Transplantation, 27, 76-80. [Google Scholar] [CrossRef] [PubMed]
|
|
[45]
|
Robinson, D.M. and Scott, L.J. (2005) Paricalcitol: A Review of Its Use in the Management of Secondary Hyperparathyroidism. Drugs, 65, 559-576. [Google Scholar] [CrossRef] [PubMed]
|
|
[46]
|
Abboud, H., Coyne, D., Smolenski, O., et al. (2006) A Comparison of Dosing Regimens of Paricalcitol Capsule for the Treatment of Secondary Hyperparathyroidism in CKD Stages 3 and 4. American Journal of Nephrology, 26, 105-114. [Google Scholar] [CrossRef] [PubMed]
|
|
[47]
|
Coyne, D., Acharya, M., Qiu, P., et al. (2006) Paricalcitol Capsule for the Treatment of Secondary Hyperparathyroidism in Stages 3 and 4 CKD. American Journal of Kidney Diseases, 47, 263-276. [Google Scholar] [CrossRef] [PubMed]
|
|
[48]
|
Trillini, M., Cortinovis, M., Ruggenenti, P., et al. (2015) Paricalci-tol for Secondary Hyperparathyroidism in Renal Transplantation. Journal of the American Society of Nephrology, 26, 1205-1214. [Google Scholar] [CrossRef]
|
|
[49]
|
Cruzado, J.M., Lauzurica, R., Pascual, J., et al. (2018) Paricalcitol versus Calcifediol for Treating Hyperparathyroidism in Kidney Transplant Recipients. Kidney International Reports, 3, 122-132. [Google Scholar] [CrossRef] [PubMed]
|
|
[50]
|
Zhang, T., Ju, H., Chen, H. and Wen, W. (2019) Com-parison of Paricalcitol and Calcitriol in Dialysis Patients with Secondary Hyperparathyroidism: A Meta-Analysis of Randomized Controlled Studies: Paricalcitol and Calcitriol for Secondary Hyperparathyroidism. Therapeutic Apheresis and Dialysis, 23, 73-79. [Google Scholar] [CrossRef] [PubMed]
|
|
[51]
|
李丽, 李灿霞. 超声引导下治疗继发性甲状旁腺亢进的价值[J]. 中国超声诊断杂志, 2005(4): 300-301.
|
|
[52]
|
Xie, S., Yu, Y., Liu, Y., et al. (2022) Effectiveness and Safety of Ultra-sound-Guided Local Paricalcitol Injection in Treating Secondary Hyperparathyroidism in ESRD: A Retrospective Study. Journal of Clinical Medicine, 11, 6860. [Google Scholar] [CrossRef] [PubMed]
|
|
[53]
|
Miyakogawa, T., Kanai, G., Tatsumi, R., et al. (2017) Feasibility of Photodynamic Therapy for Secondary Hyperparathyroidism in Chronic Renal Failure Rats. Clinical and Experimental Nephrology, 21, 563-572. [Google Scholar] [CrossRef] [PubMed]
|
|
[54]
|
Campos, P. and Herbison, A.E. (2014) Optogenetic Activation of GnRH Neurons Reveals Minimal Requirements for Pulsatile Luteinizing Hormone Secretion. Proceedings of the Nation-al Academy of Sciences of the United States of America, 111, 18387-18392. [Google Scholar] [CrossRef] [PubMed]
|
|
[55]
|
Liu, Y., Zhang, L., Hu, N., et al. (2022) An Optogenetic Approach for Regulating Human Parathyroid Hormone Secretion. Nature Communications, 13, 771. [Google Scholar] [CrossRef] [PubMed]
|